CONMED CORP (CNMD)
Health Care · Surgical and medical instruments · NYSE
CONMED is a global medical technology company specializing in innovative surgical devices and equipment for minimally invasive procedures.
What CONMED CORP does
CONMED Corporation is a global medical technology company that develops and markets surgical devices and related equipment for minimally invasive procedures. The company provides a range of products used by surgeons and physicians in the specialties of orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
Themes: minimally invasive surgery, orthopedic surgery, endoscopy, electrosurgery
Fundamentals
- Price$45.11 as of 2026-10-08 close
- Market cap$1.4B as of 2026-07-27 (share count; price 2026-10-08)
- 1-year return-3.0% 2025-10-08 close $46.52 → 2026-10-08 close $45.11
- P/E24.42 as of 2026-10-08
- Net margin+3.4% FY2025, SEC XBRL
- Gross margin+54.6% FY2025, SEC XBRL
- ROE+4.6% FY2025, SEC XBRL
- Debt / equity0.80 as of 2026-09-03
- Revenue growth (YoY)+3.4% as of 2026-09-03
- Revenue CAGR (3y)+9.6% SEC XBRL
- Beta0.93 as of 2026-09-03
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.8%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
How CNMD compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, CNMD's dividend was covered by reported results (earnings payout 53%, free-cash-flow payout 16%). This describes past coverage, not a forecast.
- Earnings payout53% dividends / net income
- Free-cash-flow payout16% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How CONMED CORP looks technically
CONMED CORP (CNMD) is trading 9.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 38 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 15.9% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 9.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $48.06 | $48.06 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $41.08 | $41.08 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 48.41. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 38 trading days ago — a "golden cross", a bullish long-term signal | 38 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 43.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($43.97 to $48.25) — its "stochastic" reading is 27 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 26.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $53.66 | $53.66 |
|---|---|---|
| From the 52-week high | it is 15.9% below its 52-week high (its highest price of the past year) | -15.9% |
| Above the 52-week low | it is 43.5% above its 52-week low (its lowest price of the past year) | +43.5% |
| Below the 52-week high | it is 15.9% below its highest point of the past year | 15.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 48 trading days ago | 48 sessions |
| All-time high | its highest closing price on record is $159.11 (set on 2021-11-05) | $159.11 |
| Given back of the 52-week move | over the past year its closes ranged ($32.11 to $51.86), and it has given back roughly a third of its rise from last year’s low — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $39.02 to $39.65. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.2% |
| From the all-time high | it is 71.6% below its all-time high | -71.7% |
| Nearest price level | it is trading 0.9% below a resistance level at $45.52 — a price it turned at five times since 2025-04-21, most recently on 2026-07-16. Since 2024-10-08 it has 6 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.9% |
| All-time low | its lowest closing price on record is $8.00 (set on 2000-08-23) | $8.00 |
| Above the all-time low | it is 463.9% above its all-time low | +463.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move | 7th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.57 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.57 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $44.23 and $47.59 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $44.23 – $45.91 – $47.59 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 2.6 daily ranges above its 200-day average price (9.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.44× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 51 sessions ago and has not traded back through the level it left behind at 43.51 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.1% gap up opened on 2026-10-02 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.2 percentage points (the stock lost 3.2% while the market gained 1.0%) | -4.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 30.5 percentage points (the stock gained 34.3% while the market gained 3.8%) | +30.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 14.9 percentage points (the stock gained 32.4% while the market gained 17.5%) | +14.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 18.0 percentage points (the stock lost 3.0% while the market gained 15.0%) | -18.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 15.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $40.94 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +10.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is under water. That average is $47.85 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -5.7% |
Price levels it has turned at before
CNMD last closed at $45.11 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $45.52 | Resistance | 0.9% above the last close | turned there five times · 2025-04-21 to 2026-07-16 |
| $47.20 | Resistance | 4.6% above the last close | turned there twice · 2025-07-21 to 2026-02-26 |
| $48.30 | Resistance | 7.1% above the last close | turned there four times · 2025-04-30 to 2026-09-16 |
| $40.81 | Support | 9.5% below the last close | turned there twice · 2026-04-21 to 2026-07-23 |
| $39.88 | Support | 11.6% below the last close | turned there twice · 2025-11-20 to 2026-01-13 |
| $38.47 | Support | 14.7% below the last close | turned there three times · 2025-12-10 to 2026-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $48.41.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $46.30 and $48.41 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $44.39.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$45.50 range $43.00 – $49.00; median $45.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CNMD
- Consensus EPS estimate$1.00 next reporting period, as of 2026-10-08
- Estimate change, 30 days$0.00 (0.0%) from $1.00, on 2026-09-03, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on continued market acceptance of minimally invasive surgical procedures.","Risks associated with integrating acquired businesses and product lines.","Potential supply chain disruptions and fluctuations in raw material or component costs."]
What changed in the latest 10-Q
AI-assisted comparison of CNMD's 10-Q filed 2026-07-29 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-29) states the Company received $10.2 million of IEEPA tariff refunds during the second quarter of 2026, of which $8.5 million was recorded in cost of goods sold and the remaining was recorded to inventory.
- Newer filing (2026-07-29) updates the product line percentage table to cover three and six months ended June 30, 2026 and 2025, showing Orthopedic surgery at 44% and 41% (Q2), 45% and 42% (six months), and General surgery at 56% and 59% (Q2), 55% and 58% (six months).
- Newer filing (2026-07-29) states approximately 86% of revenues derived from single-use products.
- Newer filing (2026-07-29) states international sales approximated 47% and 44% of consolidated net sales for the six months ended June 30, 2026 and 2025, respectively.
- Removed:
- Older filing (2026-04-30) contained a product line percentage table covering three months ended March 31, 2026 and 2025: Orthopedic surgery 47% and 43%, General surgery 53% and 57%.
- Older filing (2026-04-30) stated approximately 85% of revenues derived from single-use products.
- Older filing (2026-04-30) stated international sales approximated 45% and 43% of consolidated net sales for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-04-30) stated the Company had not recorded any receivables related to potential IEEPA tariff refunds because review and approval from U.S. Customs and Border Protection was required.
- Reworded:
- Business Environment paragraph: newer filing (2026-07-29) replaces the older statement that no receivables had been recorded for IEEPA tariff refunds with a statement that the Company 'received $10.2 million of IEEPA tariff refunds during the second quarter of 2026, of which $8.5 million was recorded in cost of goods sold and the remaining was recorded to inventory.'
- Notes:
- The newer filing text appears truncated at the end of the Business Environment section (ends with 'See "'), so changes beyond that point cannot be assessed.
- Page number changed from 19 (older) to 20 (newer) at the Table of Contents reference.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CNMD — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CNMD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 6,562,777
- Reported value $214,799,700
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CNMD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CNMD had 2,137,300 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CNMD had 7.14% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.31 days to cover at the same settlement.
- Reported short interest (shares) 2,137,300
- Short interest (% of shares outstanding) 7.14%
- Prior settlement (shares) 2,264,209
- Reported change -5.61%
- Days to cover (reported) 7.31
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Stryker (SYK)
- Smith & Nephew
- Johnson & Johnson (JNJ)
- Medtronic (MDT)
- Arthrex
- Olympus (OCPNY)
- Karl Storz
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CNMD vs…
CONMED CORP is found in…
Frequently asked questions
What does CONMED CORP (CNMD) do?
CONMED Corporation is a global medical technology company that develops and markets surgical devices and related equipment for minimally invasive procedures. The company provides a range of products used by surgeons and physicians in the specialties of orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology.
What sector is CONMED CORP (CNMD) in?
CONMED CORP (CNMD) is classified in the Health Care sector. Its industry is Surgical and medical instruments. It trades on NYSE.
Does CNMD pay a dividend?
Yes — CONMED CORP (CNMD) pays a dividend, with an indicated yield of about 1.76% and 1-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are CONMED CORP's (CNMD) competitors?
Notable peers of CONMED CORP (CNMD) include Stryker, Smith & Nephew, Johnson & Johnson, Medtronic and Arthrex. This peer set is informational only — not financial advice.
Is CONMED CORP (CNMD) overbought or oversold right now?
CONMED CORP (CNMD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CNMD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.